Liraglutide in cardiovascular conditions

Abstract

The present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine.

1 . A method for reducing the development of a major adverse cardiovascular event (MACE), comprising
 administering liraglutide in a therapeutically effective amount to a subject in need thereof,   wherein the subject has type 2 diabetes and one or more risk factors of vascular disease.   
     
     
         2 . The method according to  claim 1 , wherein the MACE is selected from the group consisting of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, hospitalization for unstable angina pectoris, and hospitalization for chronic heart failure. 
     
     
         3 . The method according to  claim 2 , wherein the MACE is selected from the group consisting of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. 
     
     
         4 . The method according to  claim 1 , wherein the vascular disease is selected from the group consisting of cardiovascular disease, cerebrovascular disease, peripheral vascular disease, chronic renal failure, and chronic heart failure. 
     
     
         5 . The method according to  claim 4 , wherein the vascular disease is cardiovascular disease. 
     
     
         6 . The method according to  claim 1 , wherein the one or more risk factors is selected from the group consisting of microalbuminuria, proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction, and an ankle/brachial index <0.9. 
     
     
         7 . The method according to  claim 1 , wherein the subject is being administered cardiovascular medication. 
     
     
         8 . A method for reducing the development of a major adverse cardiovascular event (MACE), comprising
 administering liraglutide in a therapeutically effective amount to a subject in need thereof,   wherein the subject has type 2 diabetes and one or more risk factors of cardiovascular disease,   wherein the subject is being administered cardiovascular medication, and   wherein the MACE is selected from the group consisting of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.   
     
     
         9 . The method according to  claim 8 , wherein the one or more risk factors is selected from the group consisting of microalbuminuria, proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction, and an ankle/brachial index <0.9. 
     
     
         10 . The method according to  claim 1 , wherein the subject is ≥60 years of age.